Nonprescription headache remedies save consumers $4.23 bil. annually -- Kline study.
This article was originally published in The Tan Sheet
Executive Summary
Rx-to-OTC SWITCH PRODUCTS SAVED CONSUMERS $12.88 BIL. IN 1996, according to a study conducted by Fairfield, N.J.-based Kline & Company for the Nonprescription Drug Manufacturers Association. Presented at NDMA's May 15-18 annual meeting in White Sulphur Springs, W.Va., the study found that the savings generated by switch products represented 63% of the total savings attributable to OTCs. "It is clear that the Rx-to-OTC switch process contributes greatly to the continued value of OTC products," Kline maintained
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.